Lifeworks Advisors LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 25.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission ...

Pfizer ($PFE) has filed a lawsuit in the Delaware Court of Chancery against Metsera ($MTSR), a U.S.-based obesity biotech ...

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and ...

Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently talked about. During the lightning round, when a caller asked about the stock, Cramer commented: “I don’t know what to say about Pfizer.

Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential ...

Novo Nordisk ups its bid to acquire Metsera, intensifying the obesity drug market race and challenging Pfizer.

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $30.0 for Pfizer during the past quarter. Looking at the volume ...

Pfizer Inc. (NYSE:PFE) is one of the Best Stocks to Buy for High Returns Heading into 2026. On October 27, Berenberg Bank ...

In the latest close session, Pfizer (PFE) was down 1.09% at $24.50. This move lagged the S&P 500's daily gain of 0.23%. Meanwhile, the Dow experienced a rise of 0.34%, and the technology-dominated ...